We found that 1.097% (120 of 10,935) of GPAP participants harbour pathogenic or likely pathogenic heterozygous SPG7 variants, while only 0.240% (5 out of 2,087) of our neuropathy cohort. Here, SPG7 is linked to neuropathy.